JP2015128433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015128433A5 JP2015128433A5 JP2015030813A JP2015030813A JP2015128433A5 JP 2015128433 A5 JP2015128433 A5 JP 2015128433A5 JP 2015030813 A JP2015030813 A JP 2015030813A JP 2015030813 A JP2015030813 A JP 2015030813A JP 2015128433 A5 JP2015128433 A5 JP 2015128433A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- sequence set
- nucleotide sequence
- stretch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 89
- 239000002773 nucleotide Substances 0.000 claims 85
- 150000007523 nucleic acids Chemical class 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 230000000295 complement effect Effects 0.000 claims 6
- 239000002502 liposome Substances 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 239000002479 lipoplex Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- BKHMAOXOKNEKHL-NNJYRKLXSA-N (5s)-2,3,5-triamino-8-(diaminomethylideneamino)-n-hexadecyl-n-[(z)-octadec-9-enyl]-4-oxooctanamide;trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCCCN(C(=O)C(N)C(N)C(=O)[C@@H](N)CCCNC(N)=N)CCCCCCCC\C=C/CCCCCCCC BKHMAOXOKNEKHL-NNJYRKLXSA-N 0.000 claims 1
- XLPHMKQBBCKEFO-DHYROEPTSA-N 2-azaniumylethyl [(2r)-2,3-bis(3,7,11,15-tetramethylhexadecanoyloxy)propyl] phosphate Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C XLPHMKQBBCKEFO-DHYROEPTSA-N 0.000 claims 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- SVJSSXUQZWZCNC-ZUDXCALOSA-N [Na].C(CCCCCCCCCCCCCCCCC)(=O)C(OP(OC[C@@H](CO)O)(=O)O)CN Chemical compound [Na].C(CCCCCCCCCCCCCCCCC)(=O)C(OP(OC[C@@H](CO)O)(=O)O)CN SVJSSXUQZWZCNC-ZUDXCALOSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06015262 | 2006-07-21 | ||
| EP06015262.6 | 2006-07-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013034653A Division JP2013172714A (ja) | 2006-07-21 | 2013-02-25 | プロテインキナーゼ３の発現を阻害するための手段 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015128433A JP2015128433A (ja) | 2015-07-16 |
| JP2015128433A5 true JP2015128433A5 (enExample) | 2015-08-27 |
Family
ID=38663298
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519879A Pending JP2009544281A (ja) | 2006-07-21 | 2007-07-20 | プロテインキナーゼ３の発現を阻害するための手段 |
| JP2013034653A Ceased JP2013172714A (ja) | 2006-07-21 | 2013-02-25 | プロテインキナーゼ３の発現を阻害するための手段 |
| JP2015030813A Pending JP2015128433A (ja) | 2006-07-21 | 2015-02-19 | プロテインキナーゼ３の発現を阻害するための手段 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519879A Pending JP2009544281A (ja) | 2006-07-21 | 2007-07-20 | プロテインキナーゼ３の発現を阻害するための手段 |
| JP2013034653A Ceased JP2013172714A (ja) | 2006-07-21 | 2013-02-25 | プロテインキナーゼ３の発現を阻害するための手段 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8232256B2 (enExample) |
| EP (2) | EP2546337A1 (enExample) |
| JP (3) | JP2009544281A (enExample) |
| KR (1) | KR101670085B1 (enExample) |
| CN (3) | CN104531701A (enExample) |
| AU (1) | AU2007276388A1 (enExample) |
| BR (1) | BRPI0714875A2 (enExample) |
| CA (1) | CA2658550C (enExample) |
| HK (1) | HK1208701A1 (enExample) |
| MX (1) | MX2009000654A (enExample) |
| RU (1) | RU2553561C2 (enExample) |
| WO (1) | WO2008009477A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1295611T3 (da) * | 2000-06-20 | 2010-10-04 | Dainippon Sumitomo Pharma Co | Oligonukleotid-transformerende forbindelser |
| JP4081436B2 (ja) * | 2001-06-20 | 2008-04-23 | 大日本住友製薬株式会社 | 核酸導入を促進させる方法 |
| IL166718A0 (en) * | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
| ES2548515T3 (es) | 2004-12-27 | 2015-10-19 | Silence Therapeutics Gmbh | Complejos lipídicos recubiertos con PEG y su uso |
| EP2546337A1 (en) | 2006-07-21 | 2013-01-16 | Silence Therapeutics AG | Means for inhibiting the expression of protein kinase 3 |
| WO2010110314A1 (ja) * | 2009-03-27 | 2010-09-30 | 協和発酵キリン株式会社 | 核酸を含有する肺高血圧症治療剤 |
| EP2382994A1 (en) * | 2010-04-26 | 2011-11-02 | Maurizio Victor Cattaneo | Ligand targeted nanocapsules for the delivery of RNAi and other agents |
| WO2013170960A1 (en) | 2012-05-16 | 2013-11-21 | Silence Therapeutics Ag | Use of vegfr1 as a biomarker for pkn3 inhibitor administration |
| WO2016083623A1 (en) * | 2014-11-28 | 2016-06-02 | Silence Therapeutics Gmbh | Means for the treatment of pre-eclampsia |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| RU2698199C1 (ru) * | 2018-05-18 | 2019-08-23 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт общей патологии и патофизиологии" | Средство для подавления экспрессии генов, связанных с накоплением холестерина макрофагами человека |
| CN120682233B (zh) * | 2025-08-25 | 2025-12-12 | 浙江大学 | Pkn3激酶抑制剂、药物组合物及pkn3激酶抑制剂的制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| CA2126691C (en) | 1991-12-24 | 2003-05-06 | Phillip Dan Cook | Gapped 2' modified oligonucleotides |
| CA2140343A1 (en) | 1992-07-17 | 1994-02-03 | Sean M. Sullivan | Method and reagent for treatment of animal diseases |
| US5504103A (en) | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
| US5777153A (en) | 1994-07-08 | 1998-07-07 | Gilead Sciences, Inc. | Cationic lipids |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6020526A (en) | 1995-07-21 | 2000-02-01 | Genta, Incorporated | Amide-based cationic lipids |
| ATE228529T1 (de) | 1996-08-30 | 2002-12-15 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US5989912A (en) | 1996-11-21 | 1999-11-23 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| CA2217550A1 (en) | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| US6358523B1 (en) | 1996-12-06 | 2002-03-19 | The Regents Of The University Of California | Macromolecule-lipid complexes and methods for making and regulating |
| US6001311A (en) | 1997-02-05 | 1999-12-14 | Protogene Laboratories, Inc. | Apparatus for diverse chemical synthesis using two-dimensional array |
| AU6949098A (en) | 1997-04-04 | 1998-10-30 | Valentis, Inc. | Improved methods of delivery using cationic lipids and helper lipids |
| AU7490098A (en) | 1997-05-15 | 1998-12-08 | Genzyme Corporation | Cationic amphiphile formulations |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| AU8525098A (en) | 1997-07-24 | 1999-02-16 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| JP2003528024A (ja) | 1997-12-16 | 2003-09-24 | バレンティス・インコーポレーテッド | 製剤化された核酸分子の無針注入 |
| AU3751299A (en) | 1998-04-20 | 1999-11-08 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US6150345A (en) | 1998-08-10 | 2000-11-21 | Regents Of The University Of California | Methods for promoting survival of myelin producing cells |
| FR2788275B1 (fr) | 1999-01-11 | 2002-06-14 | Lipha | ((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US7015040B2 (en) | 1999-02-26 | 2006-03-21 | Mirus Bio Corporation | Intravascular delivery of nucleic acid |
| DE60040274D1 (de) | 1999-03-10 | 2008-10-30 | Phogen Ltd | Verabreichung von nukleinsäuren und proteinen an zellen |
| CA2383244A1 (en) | 1999-05-28 | 2000-12-07 | Sugen, Inc. | Protein kinases |
| EP1064944A1 (en) | 1999-06-25 | 2001-01-03 | Schering Aktiengesellschaft | Protein kinase N inhibitor comprising Fasudil |
| AU769357B2 (en) | 1999-07-15 | 2004-01-22 | University Of British Columbia, The | Methods for preparation of lipid-encapsulated therapeutic agents |
| US6133032A (en) | 1999-09-09 | 2000-10-17 | Isis Pharmaceutical Inc. | Antisense modulation of PI3 kinase p110 beta expression |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| EP1272629A4 (en) | 2000-03-17 | 2004-12-22 | Benitec Australia Ltd | gene silencing |
| KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| AU5454801A (en) | 2000-04-20 | 2001-11-07 | Univ British Columbia | Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers |
| JP2004511572A (ja) | 2000-10-25 | 2004-04-15 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 標的化送達のための脂質製剤 |
| CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| US6394713B1 (en) * | 2001-03-05 | 2002-05-28 | Phillip E. Yates, Sr. | Drill guide apparatus |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US20030135033A1 (en) | 2002-01-04 | 2003-07-17 | Anke Klippel-Giese | Compounds and methods for the identification and/ or validation of a target |
| GB2397062B (en) | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA) |
| DE60310944T3 (de) | 2002-08-05 | 2017-08-03 | Silence Therapeutics Gmbh | Weitere neue formen von interferierende rns moleküle |
| HUE039866T2 (hu) * | 2002-08-05 | 2019-02-28 | Silence Therapeutics Gmbh | Az interferáló RNS molekulák további új formái |
| US20040156816A1 (en) | 2002-08-06 | 2004-08-12 | David Anderson | Lipid-drug complexes in reversed liquid and liquid crystalline phases |
| IL166718A0 (en) | 2002-08-14 | 2006-01-15 | Atugen Ag | Further use of protein kinase n beta |
| EP1393742A1 (en) * | 2002-08-14 | 2004-03-03 | atugen AG | Use of protein kinase N beta |
| US7635770B2 (en) | 2002-11-14 | 2009-12-22 | Dharmacon, Inc. | siRNA targeting protein kinase N-3 (PKN-3) |
| ATE422880T1 (de) | 2003-08-26 | 2009-03-15 | Smithkline Beecham Corp | Heterofunktionelle copolymere von glycerol und polyethylenglykol, ihre konjugate und zusammensetzungen |
| MXPA06012722A (es) * | 2004-05-05 | 2007-02-14 | Atugen Ag | Lipidos, complejos de lipido y su uso. |
| CA2587337A1 (en) | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
| ES2548515T3 (es) | 2004-12-27 | 2015-10-19 | Silence Therapeutics Gmbh | Complejos lipídicos recubiertos con PEG y su uso |
| WO2006074546A1 (en) | 2005-01-13 | 2006-07-20 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| EP2546337A1 (en) | 2006-07-21 | 2013-01-16 | Silence Therapeutics AG | Means for inhibiting the expression of protein kinase 3 |
| RU2360967C1 (ru) * | 2007-10-01 | 2009-07-10 | Химический факультет Московского государственного университета имени М.В.Ломоносова | Биокатализатор на основе иммобилизованных клеток бактерий для разложения метилфосфоновой кислоты и ее эфиров |
-
2007
- 2007-07-20 EP EP12005028A patent/EP2546337A1/en not_active Withdrawn
- 2007-07-20 EP EP07786240A patent/EP2049658A2/en not_active Withdrawn
- 2007-07-20 KR KR1020097000738A patent/KR101670085B1/ko not_active Expired - Fee Related
- 2007-07-20 WO PCT/EP2007/006492 patent/WO2008009477A2/en not_active Ceased
- 2007-07-20 JP JP2009519879A patent/JP2009544281A/ja active Pending
- 2007-07-20 CN CN201410643357.1A patent/CN104531701A/zh active Pending
- 2007-07-20 CN CN201110188043.3A patent/CN102321626B/zh not_active Expired - Fee Related
- 2007-07-20 RU RU2009106071/10A patent/RU2553561C2/ru not_active IP Right Cessation
- 2007-07-20 AU AU2007276388A patent/AU2007276388A1/en not_active Abandoned
- 2007-07-20 BR BRPI0714875-5A patent/BRPI0714875A2/pt not_active Application Discontinuation
- 2007-07-20 CN CNA200780026982XA patent/CN101490253A/zh active Pending
- 2007-07-20 MX MX2009000654A patent/MX2009000654A/es active IP Right Grant
- 2007-07-20 US US12/307,052 patent/US8232256B2/en not_active Expired - Fee Related
- 2007-07-20 CA CA2658550A patent/CA2658550C/en not_active Expired - Fee Related
-
2013
- 2013-02-25 JP JP2013034653A patent/JP2013172714A/ja not_active Ceased
-
2015
- 2015-02-19 JP JP2015030813A patent/JP2015128433A/ja active Pending
- 2015-09-17 HK HK15109144.9A patent/HK1208701A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015128433A5 (enExample) | ||
| JP2009544281A5 (enExample) | ||
| JP2013535212A5 (enExample) | ||
| JP2018513668A5 (enExample) | ||
| JP2017079759A5 (enExample) | ||
| JP2018512041A5 (enExample) | ||
| JP2017093448A5 (enExample) | ||
| JP2016523564A5 (enExample) | ||
| JP2018512110A5 (enExample) | ||
| JP2015142558A5 (enExample) | ||
| CN110944675A (zh) | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 | |
| JP2018518163A5 (enExample) | ||
| JP2015518721A5 (enExample) | ||
| JP2017079776A5 (enExample) | ||
| JP2013532952A5 (enExample) | ||
| JP2017537626A5 (enExample) | ||
| JP2018530530A5 (enExample) | ||
| EP4527459A3 (en) | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof | |
| JP2013511990A5 (enExample) | ||
| HRP20191232T1 (hr) | Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina) | |
| JP2017510542A5 (enExample) | ||
| JP2009514877A5 (enExample) | ||
| JP2013226147A5 (enExample) | ||
| WO2008130585A9 (en) | Wireframe nanostructures | |
| JP2012505657A5 (enExample) |